Boulder, CO, October 1, 2007 – NeuroMark, a Boulder, Colorado company, announced today the immediate availability of a genetic test to identify people at risk of suicidal ideation—thoughts of committing suicide—when prescribed an antidepressant drug. The test, called the Mark-C™ test, is expected to help restore public confidence in antidepressant medication and help to reduce a recently announced spike in suicide rates among U.S. youth. “This is an exciting example of the power of genetics to address a critical need and make important drugs safer for patients worldwide,” stated Kim Bechthold, NeuroMark’s CEO.
